AxoGen (NASDAQ:AXGN) issued its earnings results on Sunday. The medical equipment provider reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.08, MarketWatch Earnings reports. AxoGen had a negative net margin of 22.98% and a negative return on equity of 19.83%.
NASDAQ AXGN traded up $0.26 during trading hours on Tuesday, hitting $21.45. The company had a trading volume of 34,896 shares, compared to its average volume of 249,087. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.81 and a current ratio of 7.45. AxoGen has a 1-year low of $7.16 and a 1-year high of $21.76. The company has a market cap of $871.28 million, a PE ratio of -35.14 and a beta of 0.71. The business has a 50 day moving average of $19.02 and a 200-day moving average of $14.98.
A number of equities analysts recently commented on AXGN shares. Canaccord Genuity boosted their target price on shares of AxoGen from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Tuesday. Cantor Fitzgerald boosted their target price on shares of AxoGen from $16.00 to $23.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 12th. Finally, SVB Leerink boosted their target price on shares of AxoGen from $23.00 to $27.00 and gave the stock an “outperform” rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. AxoGen presently has an average rating of “Buy” and a consensus price target of $23.75.
In other AxoGen news, CEO Karen L. Zaderej sold 65,000 shares of the company’s stock in a transaction on Friday, January 8th. The shares were sold at an average price of $20.00, for a total value of $1,300,000.00. Following the completion of the transaction, the chief executive officer now owns 609,099 shares in the company, valued at $12,181,980. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 72,932 shares of company stock valued at $1,439,869 in the last 90 days. 6.94% of the stock is currently owned by insiders.
AxoGen, Inc, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Featured Story: How Does the Quiet Period Work?
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.